

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

MINGYUAN MEDICARE DEVELOPMENT COMPANY LIMITED

銘源醫療發展有限公司*

(incorporated in Bermuda with limited liability)

(Stock Code: 0233)

APPOINTMENT OF DIRECTORS

The board of directors (the “Board”) of Mingyuan Medicare Development Company Limited (the “Company”) is pleased to announce that (1) Mr. Kot Wang (“Mr. Kot”) has been appointed as an executive director of the Company with effect from 17 September 2015; and (2) Mr. Zhang Xiao Ming (“Mr. Zhang”) has been appointed as an independent non-executive director of the Company with effect from 17 September 2015.

Brief Profile of Mr. Kot

Mr. Kot Wang (葛弘), aged 58, has more than 20 years of experience in investment, management and corporate finance. Mr. Kot holds a bachelor degree from University of Electronic Science and Technology of China. Mr. Kot held senior positions in various enterprises in Hong Kong and China. Mr. Kot did not hold any directorship in any listed public companies in the last three years.

Mr. Kot does not enter into a service contract with the Company. Mr. Kot is not appointed for a specific term but is subject to retirement by rotation and re-election at the annual general meeting of the Company in accordance with the Bye-laws of the Company. The director’s fee for Mr. Kot is HK\$120,000 per annum. The emolument for Mr. Kot is determined by the Board with reference to Mr. Kot’s responsibilities and duties within the Company.

Mr. Kot does not have any relationship with any directors, senior management or substantial or controlling shareholders of the Company. As at the date of this announcement, Mr. Kot does not have any interest in shares of the Company within the meaning of Part XV of the Securities and Future Ordinance.

Save as disclosed herein, in relation to the appointment of Mr. Kot as an executive director of the Company, there is no information which is discloseable nor is/was he involved in any of the matters required to be disclosed pursuant to any of the requirements of the provisions under paragraphs 13.51(2)(h) to 13.51(2)(v) of the Listing Rules, and there is no other matter which needs to be brought to the attention of the shareholders of the Company.

Brief Profile of Mr. Zhang

Mr. Zhang Xiao Ming (張效銘), aged 31, holds a master degree in Clinical Embryology from University of Oxford in UK, a master degree in Economics and Management from the London School of Economics and Political Science, exchange student in Stanford University in US and a bachelor degree in Biomedical from The University of Manchester, UK. Mr. Zhang is currently a laboratory director in Pacific Fertility Institutes in US. Mr. Zhang did not hold any directorship in any listed public companies in the last three years.

Mr. Zhang does not enter into a service contract with the Company. Mr. Zhang is not appointed for a specific term but is subject to retirement by rotation and re-election at the annual general meeting of the Company in accordance with the Bye-laws of the Company. The director's fee for Mr. Zhang is HK\$120,000 per annum. The emolument for Mr. Zhang is determined by the Board with reference to Mr. Zhang's responsibilities and duties within the Company.

Mr. Zhang does not have any relationship with any directors, senior management or substantial or controlling shareholders of the Company. As at the date of this announcement, Mr. Zhang does not have any interest in shares of the Company within the meaning of Part XV of the Securities and Future Ordinance.

Save as disclosed herein, in relation to the appointment of Mr. Zhang as an independent non-executive director of the Company, there is no information which is discloseable nor is/was he involved in any of the matters required to be disclosed pursuant to any of the requirements of the provisions under paragraphs 13.51(2)(h) to 13.51(2)(v) of the Listing Rules, and there is no other matter which needs to be brought to the attention of the shareholders of the Company.

The Board would like to extend a warm welcome to Mr. Kot and Mr. Zhang.

By order of the Board
Mingyuan Medicare Development Company Limited
銘源醫療發展有限公司*
Yao Yuan
Chairman & CEO

Hong Kong, 17 September 2015

As at the date of this announcement, the executive directors are Mr. Yao Yuan (Chairman & CEO) and Mr. Kot Wang; non-executive director is Mr. Yu Ti Jun; the independent non-executive directors are Mr. Yao Liang, Mr. Yang Chun Bao and Mr. Zhang Xiao Ming.

** For identification purposes only*